In mice treated with LPS to cause an endotoxemia and subsequent myocardial injury, administration of Sivelestat prompted a higher survival rate by reduction of pro-inflammatory IL-6 and decreased neutrophil infiltration (Fukuta et al., 2020). The gene discussed is IL6; the disease is serum lipopolysaccharide activity.